- Home
- KYNB vs CCEL Comparison
KYNB vs CCEL Comparison
Compare KYNB & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | CCEL |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 32.7M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | KYNB | CCEL |
|---|---|---|
| Price | $7.43 | $3.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.9K | 13.9K |
| Earning Date | 03-16-2026 | 02-27-2026 |
| Dividend Yield | N/A | ★ 4.49% |
| EPS Growth | N/A | N/A |
| EPS | ★ 53.38 | N/A |
| Revenue | $8,298,000.00 | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.85 | $3.10 |
| 52 Week High | $21.94 | $8.48 |
Technical Indicators
Market Signals| Indicator | KYNB | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 40.70 |
| Support Level | $7.50 | $3.27 |
| Resistance Level | $8.25 | $3.55 |
| Average True Range (ATR) | 0.66 | 0.18 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 10.47 | 51.66 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.